Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider David Bredt sold 8,500 shares of the business's stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $14.00, for a total transaction of $119,000.00. Following the sale, the insider owned 435,142 shares in the company, valued at $6,091,988. The trade was a 1.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
David Bredt also recently made the following trade(s):
- On Tuesday, July 15th, David Bredt sold 8,500 shares of Rapport Therapeutics stock. The stock was sold at an average price of $14.00, for a total transaction of $119,000.00.
Rapport Therapeutics Price Performance
Shares of NASDAQ RAPP traded down $0.16 during midday trading on Friday, reaching $14.68. 137,409 shares of the company traded hands, compared to its average volume of 166,324. Rapport Therapeutics, Inc. has a 52 week low of $6.43 and a 52 week high of $29.74. The stock has a 50-day moving average price of $11.68 and a 200 day moving average price of $12.00. The company has a market cap of $535.82 million and a price-to-earnings ratio of -4.26.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($0.77) by $0.09. As a group, analysts expect that Rapport Therapeutics, Inc. will post -3.65 EPS for the current year.
Analyst Ratings Changes
Several equities research analysts recently commented on the stock. JMP Securities reiterated a "market outperform" rating and issued a $28.00 price objective on shares of Rapport Therapeutics in a research report on Tuesday, July 8th. Citizens Jmp began coverage on shares of Rapport Therapeutics in a report on Tuesday, April 8th. They issued a "mkt outperform" rating on the stock.
View Our Latest Research Report on RAPP
Hedge Funds Weigh In On Rapport Therapeutics
A number of institutional investors have recently bought and sold shares of the stock. TRV GP V LLC purchased a new position in Rapport Therapeutics during the 4th quarter valued at about $126,579,000. TRV GP VI LLC purchased a new position in Rapport Therapeutics during the 4th quarter valued at about $17,194,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC purchased a new position in Rapport Therapeutics during the 1st quarter valued at about $2,039,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Rapport Therapeutics by 9.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,143,384 shares of the company's stock valued at $20,285,000 after buying an additional 95,976 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Rapport Therapeutics during the 4th quarter valued at about $860,000.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
